背景:脑膜瘤术前栓塞术在减少术中失血和手术时间方面的有效性存在争议。相比之下,一些报告记录了大型脑膜瘤的手术结局改善.在这项研究中,我们回顾性地比较了脑膜瘤开颅手术的结果,术前使用稀释的N-丁基-2-氰基丙烯酸酯(NBCA)进行栓塞或未进行栓塞的情况.
方法:数据(世界卫生组织等级,辛普森等级,肿瘤最大直径,术中出血,手术时间,高血压病史,和从栓塞到开颅手术的时间)比较了2015年1月至2022年4月是否术前栓塞的初始颅内脑膜瘤患者。
结果:栓塞组56例,非栓塞组76例。经动脉栓塞的56例患者中有51例(91.1%)使用了稀释的NBCA(所有患者的浓度为13%)。2例(3.6%)患者发生永久性神经系统并发症。在最大肿瘤直径≥40mm的栓塞组中,术中出血明显减少(155vs.305毫升,分别,p<0.01)。在非栓塞组中,对于最大肿瘤直径≥30mm,高血压患者术中出血多于非高血压患者.
结论:尽管有其局限性,目前的结果表明,在一定条件下,颅内脑膜瘤术前栓塞术减少术中出血.治疗的安全性与日本神经血管内治疗注册3(JR-NET3)报告的安全性相当,脑膜瘤术前栓塞的并发症发生率为3.7%。尽管治疗集中在液体栓塞材料上。
Preoperative embolization for meningiomas is controversial regarding its effectiveness in reducing intraoperative blood loss and operative time. In contrast, some reports have documented improved surgical outcomes in large meningiomas. In this study, we retrospectively compared the outcomes of craniotomy for meningiomas with/without preoperative embolization with diluted N-butyl-2-cyanoacrylate (NBCA) primarily in a single institution.
Data (World Health Organization grade, Simpson grade, maximum tumor diameter, intraoperative bleeding, operative time, history of hypertension, and time from embolization to craniotomy) of patients with initial intracranial meningiomas were compared with or without preoperative embolization from January 2015 to April 2022.
The embolization group consisted of 56 patients and the nonembolization group included 76 patients. Diluted NBCA (13% concentration for all patients) was used in 51 of 56 patients (91.1%) who underwent transarterial embolization. Permanent neurological complications occurred in 2 (3.6%) patients. Intraoperative bleeding was significantly lower in the embolization group for a maximum tumor diameter ≥40 mm (155 vs. 305 ml, respectively, p < 0.01). In the nonembolization group, for a maximum tumor diameter ≥30 mm, patients with hypertension had more intraoperative bleeding than non-hypertensive ones.
Despite its limitations, the present results showed that, under certain conditions, preoperative embolization for intracranial meningiomas caused less intraoperative bleeding. The safety of treatment was comparable with that reported in the Japan Registry of NeuroEndovascular Therapy 3 (JR-NET3) with a complication rate of 3.7% for preoperative embolization of meningiomas, despite the treatment focused on the liquid embolization material.